The Importance of Outcome Measures in the Management of Inflammatory Rheumatic Diseases

被引:2
作者
Collada, Juan Molina [1 ,2 ]
Trives, Laura [1 ]
Castrejon, Isabel [1 ,2 ]
机构
[1] Univ Gregorio Maranon, Gen Hosp, Dept Rheumatol, Esquerdo 46, Madrid 28007, Spain
[2] Inst Invest Sanitaria Gregorio Maranon IiSGM, Madrid, Spain
关键词
outcome measures; disease activity; remission; physician management; rheumatoid arthritis; systemic lupus erythematosus; spondyloarthropathies; psoriatic arthritis; SYSTEMIC-LUPUS-ERYTHEMATOSUS; TREAT-TO-TARGET; ACTIVITY SCORE ASDAS; FORMAL JOINT COUNTS; C-REACTIVE PROTEIN; ACTIVITY INDEX; ANKYLOSING-SPONDYLITIS; AMERICAN-COLLEGE; CLINICAL-TRIALS; RHEUMATOLOGY/EUROPEAN LEAGUE;
D O I
10.2147/OARRR.S276980
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rheumatic inflammatory diseases include a diverse and heterogeneous group of multifaceted disorders in which clinical history and physical examination are essential to make treatment choices and for optimizing outcomes. Composite outcome measures have become very relevant in rheumatology to evaluate disease activity as they capture the most important dimensions of the disease into one single measure. Most outcome measures may include disease manifestations, laboratory data, physician examination as well as the patient perspective as different outcome dimensions of the disease into a simple index. These outcome measures have proved their utility for guiding treatment in treat-to-target strategies and personalized medicine, with remission being the ultimate goal. In this narrative review, we go over the most commonly used outcome measures in rheumatoid arthritis, spondyloarthropathies, including psoriatic arthritis, and systemic lupus erythematosus to provide a practical summary for clinicians for everyday routine care.
引用
收藏
页码:191 / 200
页数:10
相关论文
共 58 条
[1]  
Aletaha D, 2005, CLIN EXP RHEUMATOL, V23, pS100
[2]   Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score [J].
Aletaha, D ;
Nell, VP ;
Stamm, T ;
Uffmann, M ;
Pflugbeil, S ;
Machold, K ;
Smolen, JS .
ARTHRITIS RESEARCH & THERAPY, 2005, 7 (04) :R796-R806
[3]  
Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI [10.1136/ard.2010.138461, 10.1002/art.27584]
[4]  
Anderson JJ, 2001, ARTHRITIS RHEUM-US, V44, P1876, DOI 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO
[5]  
2-F
[6]   Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage [J].
Arora, Shilpa ;
Isenberg, David A. ;
Castrejon, Isabel .
ARTHRITIS CARE & RESEARCH, 2020, 72 :27-46
[7]   International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis [J].
Braun, J ;
Pham, T ;
Sieper, J ;
Davis, J ;
van der Linden, S ;
Dougados, M ;
van der Heijde, D .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (09) :817-824
[8]  
Castrejón I, 2014, CLIN EXP RHEUMATOL, V32, pS85
[9]  
Castrejón I, 2012, CLIN EXP RHEUMATOL, V30, pS50
[10]  
Castrejón I, 2008, CLIN EXP RHEUMATOL, V26, P769